Specific binding members against synaptophysin

Abstract

The present invention relates to specific binding members against synaptophysin, and particularly provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and optionally one or more VH CDR's with an amino acid sequence selected from SEQ ID NO. 10 and SEQ ID NO. 11; and / or an antibody VL domain selected from the group consisting of the C1-3 VL domain (SEQ ID NO. 4) and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. The invention further provides related materials such as nucleic acids, kits and compositions, and also methods of use of the binding member, for instance in targeting entities to hepatic stellate cells which are implicated in liver fibrosis.

Description

[0001] This application is a divisional application of an invention patent application with an application date of March 29, 2005, application number 200580017473.1 (international application number PCT / GB2005 / 001190), and an invention patent application titled "Specific binding member for anti-synaptophysin" . technical field [0002] The present invention relates to specific binding members directed to bind synaptophysin. Preferred embodiments of the invention employ the antibody VH and / or VL domains of the scFv fragment referred to herein as C1-3. Yet another preferred embodiment utilizes one or more complementarity determining regions (CDRs) of the C1-3 heavy chain variable region (VH) and / or light chain variable region (VL), especially in other antibody framework regions. VH C1-3. The inventors have identified a number of antibody molecules with favorable properties, especially the ability to target the outer surface of hepatic stellate cells. Background technique ...

AI Technical Summary

Problems solved by technology

[0005] A major problem with many potential anti-fibrotic agents in the past has been the inability of drugs to achieve therapeutic concentrations in hepatic stellate cells, possibly because of the proximity of hepatocytes that metabolize foreign compounds.

Images